Hummingbird Bioscience to Present Two Posters on HER3-Targeting Therapeutics at American Association for Cancer Research (AACR) Meeting 2023

Presentations highlight the robust tumor growth inhibition in preclinical models for its HER3-targeting programs HMBD-001 (HER3 mAb) and HMBD-501 (HER3 ADC) HMBD-001 used as monotherapy or in combination with cetuximab effectively inhibits tumor growth in preclinical squamous cell…

Leave a Reply

Your email address will not be published. Required fields are marked *